ISRG Stock Analysis — Intuitive Surgical
Sector: Healthcare
AI Verdict
You're paying a steep premium for ISRG at 42.2x next year's earnings, so the moat around da Vinci must keep driving double-digit growth to avoid further multiple compression.
Competitive Moat
Intuitive Surgical dominates robotic-assisted surgery with its da Vinci platform, protected by a massive installed base and high switching costs for hospitals due to surgeon training and proprietary consumables. Its recurring revenue model from instruments and service contracts makes its business sticky and hard to disrupt.
Summary
ISRG's da Vinci robotic surgery system is the gold standard in minimally invasive procedures, driving recurring revenue from every surgery performed.
Where It Stands
ISRG is down -25.18% over the past year, trades at 42.2x next year's earnings (nearly double the healthcare sector median of 22x), and its RSI of 36.4 signals shares are approaching oversold territory.
Key Metrics
- RSI: 36.4 — Near Oversold
- Trailing P/E: 51.0x
- Forward P/E: 42.2x
- PEG Ratio: 1.86
- Earnings Growth: +0.2%
- Revenue Growth: +0.2%
- Market Cap: $148.8B
- 1-Year Return: -25.18%
- 52-Week High: $603.88
- 52-Week Low: $427.84
Analyst Consensus
29 Buy · 11 Hold · 1 Sell (41 analysts)
Bull Case
Analysts expect 20.8% EPS growth next year, so you're paying 42.2x forward earnings for a company with rare scale and 20.5% revenue growth.
Bear Case
If the P/E reverts just halfway toward the sector median (from 42.2x to 32x), that would wipe out another 24% off the stock price even if earnings hit targets.
Catalyst to Watch
Watch for regulatory approvals or major hospital system wins—either could accelerate procedure growth and justify the premium multiple.